Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Sihuan Pharmaceutical Holdings Group ( (HK:0460) ).
Sihuan Pharmaceutical Holdings Group Ltd. announced significant results from a phase 3 clinical trial of its innovative drug Bireociclib, in combination with Fulvestrant, for treating HR+/HER2- advanced breast cancer. The study, published in Nature Communications, demonstrated that the combination therapy significantly improved progression-free survival compared to Fulvestrant alone, marking a notable advancement in treatment options for complex and refractory breast cancer cases. This achievement underscores Sihuan Pharmaceutical’s strong R&D capabilities and commitment to addressing unmet clinical needs, enhancing its position in the pharmaceutical industry.
More about Sihuan Pharmaceutical Holdings Group
Sihuan Pharmaceutical Holdings Group Ltd. is a pharmaceutical company with a focus on innovative drug development, particularly in areas such as oncology and digestion. Its subsidiary, Xuanzhu Biopharmaceutical, is dedicated to the research, development, production, and commercialization of class 1 drugs with proprietary intellectual property rights, leveraging both small molecule chemistry and large molecule biologics R&D platforms.
YTD Price Performance: -2.00%
Technical Sentiment Signal: Strong Buy
Current Market Cap: $672.7M
For a thorough assessment of 0460 stock, go to TipRanks’ Stock Analysis page.